Billionaire investor Carl Icahn is taking aim at Forest Laboratories Inc’s (FRX.N) longtime chief executive officer as he seeks to shake up the U.S. drugmaker’s board. In a U.S. securities filing, Icahn criticized Forest’s board for spending to defend CEO Howard Solomon, who is challenging a potential U.S. government action to exclude him from participating in federal healthcare programs. The move followed a $313 million company settlement last year for improper marketing and distribution of its drugs.
